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ABSTRACT
Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose,
since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a
review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was
higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring
special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life
administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.
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RESUMO
Fingolimode é um tratamento novo e eficaz para esclerose múltipla (EM). A administração desta droga requer atenção especial para a
primeira dose, uma vez que eventos adversos cardiovasculares podem ser observados nas seis horas iniciais da ingestão de fingolimode. O
presente estudo consistiu de uma revisão de dados cardiovasculares de 180 pacientes com EM ao receberem a primeira dose de
fingolimode. A taxa de bradicardia nestes pacientes foi maior do que aquele observada em estudos clínicos que tem critérios de inclusão
muito rigorosos para seleção de pacientes. Menos de 10% dos casos necessitou de atenção especial, mas não houve casos fatais. Todos
os pacientes exceto por um continuaram o tratamento após esta dose inicial. Este é o primeiro relato de dados de administração de
fingolimode na vida real de pacientes brasileiros com EM, e um dos poucos trabalhos com estas características no mundo.
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The efficacy of fingolimod, the innovative oral drug therapy
for multiple sclerosis (MS) has been shown in clinical trials and
in medical practice1. It is widely recommended that, during the
first dose of fingolimod, patients should be on an appropriate
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medical environment capable to deal with potential cardio-
vascular complications1,2. Transient effects on heart rate are
explained by transient agonism of sphingosine-1P receptors
in atrial myocytes3. As yet, there has been no report on the
safety of the first dose of fingolimod in Brazilian patients with
MS where the protocol recommends medical observation and
cardiovascular monitoring for at least six hours. In fact, except
for results on clinical trials with very strict inclusion criteria for
patients4, there are few reports on the real life experience with
the first dose of fingolimod2,5.
Retrospective data were collected for 180 patients aged
over 18 years diagnosed with MS according to the revised
McDonald criteria6. These patients were closely monitored
during the first dose of fingolimod. Each MS Unit had obtained
authorization by the Ethics Committee to proceed with the
treatment with fingolimod. Patients were informed that they
should contact their doctor in case of any signs or symptoms
beyond the observation period (minimum six hours).
Gender, age, cardiac rate and blood pressure were regis-
tered for all cases. There were 132 women and 48 men, with
an average age of 36.8 years (median=36 years, range=19 to
66 years). Five patients had high blood pressure and four
patients had right or left branch block before medication.
They were kept under observation for longer than six hours
and did not develop complications. Two patients had sinus
tachycardia and two other patients had sinus bradycardia at
the first ECG registration. They did not develop complica-
tions. Twelve other patients (6.7%) were kept under medical
observation for longer than six hours due to symptomatic
bradycardia, while three of them (1.7%) needed to be in
intensive care units for developing right branch block or
second-degree atrioventricular block. There were no cases
of other severe complications and no cases of death among
these patients during or after the initial dose, despite the
description of possible delayed asystole7. At present, 99.4%
of the patients reported here continue the treatment
with fingolimod.
Figure shows a summary of data regarding cardiac rate,
systolic and diastolic blood pressure up to six hours for all
patients. When assessed by one-way ANOVA, the 3rd and
4th hours of observation showed a significant (P,0.001)
lower heart rate than other time points.
Figure also shows the variation in systolic and diastolic
blood pressure during the observation period of six
hours. There were no isolated cases of marked hypo or
hypertension peaks during the whole observation period.
When assessed by one-way ANOVA, no significant dif-
ferences in either systolic or diastolic blood pressure
were observed.
The FREEDOMS clinical trial of fingolimod and its exten-
sions showed less than 1% cases of bradycardia during the
first dose8. The study of Ontaneda et al. which dealt with
clinical practice data also demonstrated 1% rate of bradycar-
dia as a complication of fingolimod initiation2. A recent
Italian study reported 2% cardiovascular adverse events in
patients taking the first dose of fingolimod, mainly bradycar-
dia and atrio-ventricular block5. The Italian study used a
method similar to ours, reporting the results of daily medical
practices. For Brazilian patients in the real life series this
observation was higher, even though there was a return to
normal cardiac rate after a period of up to ten hours in all
but three cases.
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Figure. Average values and standard deviation for the heart rate of 180 patients undergoing the first dose of fingolimod. Data
registered over six hours of medical observation. *P,0.001 in relation to other time points (A). Average values and standard
deviation for the systolic (upper values) and diastolic (lower values) blood pressure of 180 patients undergoing the first dose of
fingolimod. Data registered over six hours of medical observation (B).
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It is imperative to register the cardiovascular parameters
during the first dose of fingolimod9. A much larger retro-
spective and prospective Brazilian database should be
created in order to observe cardiovascular parameters in
patients receiving the first dose of fingolimod in our country.
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